# Cordis acquires MedAlliance for USD 1.135 billion

Cordis, a US medical device company, acquired Swiss-based MedAlliance for USD 1.135 billion. MedAlliance develops the Sirolimus Drug-Eluting Balloon (Selution SLR) for stentless angioplasty.

- Type: Acquisition
- Announced: 2023-10-05
- Where: Switzerland
- Value: $1.14B
- Status: completed
- Products: Sirolimus Drug-Eluting Balloon, Selution SLR
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Cordis](https://endata.com/companies/48117.md) (acquirer)
- [MedAlliance](https://endata.com/companies/48118.md) (target)

## Sources

- [prnewswire.com](https://www.prnewswire.com/in/news-releases/medalliance-a-pioneering-medical-device-startup-acquired-by-cordis-of-usa-in-a-landmark-usd-1-135-billion-deal-301947440.html), 2023-10-05: "MedAlliance, a pioneer in drug device combinations, has harnessed innovation to provide a ground-breaking solution - the patented Sirolimus Drug Eluting Balloon, Selution SLR."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.